Condition: Focal Segmental Glomerulosclerosis · Sponsor: Akebia Therapeutics
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label extension for an additional 24 weeks.
This description comes directly from the study's public registry record.
Akebia Therapeutics · 16178446128 · trials@akebia.com
Always discuss trial participation with your own doctor first.
| Investigator Site #2 | Chula Vista, California, United States | Recruiting |
| Investigator Site #14 | Los Angeles, California, United States | Recruiting |
| Investigator Site #12 | San Dimas, California, United States | Recruiting |
| Investigator Site #13 | Arvada, Colorado, United States | Recruiting |
| Investigator Site #17 | Boca Raton, Florida, United States | Recruiting |
| Investigator Site #6 | Coral Springs, Florida, United States | Recruiting |
| Investigator Site #7 | Miami, Florida, United States | Recruiting |
| Investigator Site #8 | Orlando, Florida, United States | Recruiting |
| Investigator Site # 1 | Lawrenceville, Georgia, United States | Recruiting |
| Investigator Site #3 | Chicago, Illinois, United States | Terminated |
| Investigator Site #11 | Louisville, Kentucky, United States | Recruiting |
| Investigator Site #15 | Livonia, Michigan, United States | Recruiting |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07268638